NASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Forecast, Price & News $33.19 +1.06 (+3.30%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$31.70▼$33.2550-Day Range$30.29▼$36.6252-Week Range$19.85▼$48.40Volume369,374 shsAverage Volume536,930 shsMarket Capitalization$1.57 billionP/E RatioN/ADividend YieldN/APrice Target$63.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Celldex Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside91.3% Upside$63.50 Price TargetShort InterestBearish11.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.64) to ($2.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.64 out of 5 starsMedical Sector824th out of 983 stocksDiagnostic Substances Industry12th out of 15 stocks 3.5 Analyst's Opinion Consensus RatingCelldex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $63.50, Celldex Therapeutics has a forecasted upside of 91.3% from its current price of $33.19.Amount of Analyst CoverageCelldex Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.47% of the outstanding shares of Celldex Therapeutics have been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Celldex Therapeutics has recently increased by 1.12%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLDX. Previous Next 3.3 News and Social Media Coverage News SentimentCelldex Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Celldex Therapeutics this week, compared to 2 articles on an average week.Search Interest9 people have searched for CLDX on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Celldex Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.64) to ($2.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -13.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -13.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 5.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Celldex Therapeutics (NASDAQ:CLDX) StockCelldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.Read More Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Stock News HeadlinesMay 31, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Celldex TherapeuticsMay 31, 2023 | finance.yahoo.comCelldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced MalignanciesJune 3, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 23, 2023 | finance.yahoo.comCelldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth PlansMay 18, 2023 | seekingalpha.comCelldex Therapeutics: Revolutionizing Cancer Care With Innovative ImmunotherapiesMay 15, 2023 | finance.yahoo.comCelldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™May 8, 2023 | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Price Target Cut to $54.00 by Analysts at Cantor FitzgeraldMay 6, 2023 | msn.comCantor Fitzgerald Maintains Celldex Therapeutics (CLDX) Overweight RecommendationJune 3, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 5, 2023 | msn.comHC Wainwright & Co. Reiterates Celldex Therapeutics (CLDX) Buy RecommendationMay 4, 2023 | msn.comCelldex Therapeutics: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comCelldex Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 18, 2023 | finance.yahoo.comStrength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?April 15, 2023 | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading VolumeApril 12, 2023 | benzinga.comIs Celldex Therapeutics, Inc. (CLDX) a Smart Choice in Biotechnology Monday?April 12, 2023 | finance.yahoo.comAre Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 42%?April 12, 2023 | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.4%April 5, 2023 | americanbankingnews.comShort Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Increases By 5.5%March 23, 2023 | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading VolumeMarch 23, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Buy Rating on Celldex (CLDX)March 22, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Celldex (CLDX)March 2, 2023 | finanznachrichten.deCelldex Therapeutics, Inc.: Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate UpdateMarch 2, 2023 | finance.yahoo.comCelldex Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In LineMarch 1, 2023 | finance.yahoo.comCelldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate UpdateFebruary 27, 2023 | msn.comCelldex gains 12% on Phase 1 data for urticaria candidateFebruary 27, 2023 | benzinga.comWhy Celldex Therapeutics Shares Are Trading Higher TodayFebruary 26, 2023 | finance.yahoo.comCelldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023See More Headlines CLDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLDX Company Calendar Last Earnings11/09/2021Today6/02/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CLDX CUSIP15117B10 CIK744218 Webwww.celldex.com Phone(908) 454-7120Fax908-454-1911Employees132Year Founded1983Price Target and Rating Average Stock Price Forecast$63.50 High Stock Price Forecast$73.00 Low Stock Price Forecast$54.00 Forecasted Upside/Downside+91.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,320,000.00 Net Margins-3,766.22% Pretax Margin-3,766.22% Return on Equity-32.84% Return on Assets-30.35% Debt Debt-to-Equity RatioN/A Current Ratio19.03 Quick Ratio19.03 Sales & Book Value Annual Sales$2.36 million Price / Sales664.50 Cash FlowN/A Price / Cash FlowN/A Book Value$6.41 per share Price / Book5.18Miscellaneous Outstanding Shares47,250,000Free Float45,504,000Market Cap$1.57 billion OptionableOptionable Beta2.12 Social Links Key ExecutivesAnthony S. MarucciPresident, Chief Executive Officer & DirectorSam MartinCFO, Secretary, Treasurer & Senior Vice PresidentTibor KelerChief Scientific Officer & Executive VPDiane C. YoungChief Medical Officer & Senior Vice PresidentElizabeth CrowleyChief Product Development Officer & Senior VPKey CompetitorsMyriad GeneticsNASDAQ:MYGNHeskaNASDAQ:HSKAIntellia TherapeuticsNASDAQ:NTLANeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 23,558 shares on 5/18/2023Ownership: 0.152%New York State Common Retirement FundSold 5,134 shares on 5/18/2023Ownership: 0.058%State Street CorpBought 11,071 shares on 5/16/2023Ownership: 4.873%Geode Capital Management LLCBought 42,173 shares on 5/16/2023Ownership: 1.959%AQR Capital Management LLCSold 1,738 shares on 5/16/2023Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions CLDX Stock - Frequently Asked Questions Should I buy or sell Celldex Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLDX shares. View CLDX analyst ratings or view top-rated stocks. What is Celldex Therapeutics' stock price forecast for 2023? 3 brokerages have issued twelve-month price targets for Celldex Therapeutics' shares. Their CLDX share price forecasts range from $54.00 to $73.00. On average, they expect the company's share price to reach $63.50 in the next twelve months. This suggests a possible upside of 91.3% from the stock's current price. View analysts price targets for CLDX or view top-rated stocks among Wall Street analysts. How have CLDX shares performed in 2023? Celldex Therapeutics' stock was trading at $44.57 at the beginning of 2023. Since then, CLDX stock has decreased by 25.5% and is now trading at $33.19. View the best growth stocks for 2023 here. When is Celldex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our CLDX earnings forecast. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The biopharmaceutical company had revenue of $0.15 million for the quarter, compared to analysts' expectations of $1.70 million. Celldex Therapeutics had a negative net margin of 3,766.22% and a negative trailing twelve-month return on equity of 32.84%. What ETFs hold Celldex Therapeutics' stock? ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY), Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC). When did Celldex Therapeutics' stock split? Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX). What is Celldex Therapeutics' stock symbol? Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX." Who are Celldex Therapeutics' major shareholders? Celldex Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), Wellington Management Group LLP (8.85%), BlackRock Inc. (6.88%), State Street Corp (4.87%), Jennison Associates LLC (3.35%) and Geode Capital Management LLC (1.96%). Insiders that own company stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celldex Therapeutics' stock price today? One share of CLDX stock can currently be purchased for approximately $33.19. How much money does Celldex Therapeutics make? Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.57 billion and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-112,320,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis. How many employees does Celldex Therapeutics have? The company employs 132 workers across the globe. How can I contact Celldex Therapeutics? Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 454-7120, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911. This page (NASDAQ:CLDX) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.